155 related articles for article (PubMed ID: 20631307)
21. IFN-gamma dictates allograft fate via opposing effects on the graft and on recipient CD8 T cell responses.
Coley SM; Ford ML; Hanna SC; Wagener ME; Kirk AD; Larsen CP
J Immunol; 2009 Jan; 182(1):225-33. PubMed ID: 19109153
[TBL] [Abstract][Full Text] [Related]
22. Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells.
Satake A; Inoue T; Kubo S; Taniguchi Y; Imado T; Fujioka T; Horiuchi M; Xu Y; Ikegame K; Yoshihara S; Kaida K; Tamaki H; Okada M; Okamura H; Ogawa H
Int J Hematol; 2010 Apr; 91(3):485-97. PubMed ID: 20300982
[TBL] [Abstract][Full Text] [Related]
23. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
24. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R
Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135
[TBL] [Abstract][Full Text] [Related]
25. Donor CD8 T cells and IFN-gamma are critical for sex-based differences in donor CD4 T cell engraftment and lupus-like phenotype in short-term chronic graft-versus-host disease mice.
Foster AD; Soloviova K; Puliaeva I; Puliaiev M; Puliaev R; Finkelman F; Via CS
J Immunol; 2011 Jun; 186(11):6238-54. PubMed ID: 21531893
[TBL] [Abstract][Full Text] [Related]
26. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation.
Saito TI; Rubio MT; Sykes M
Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820
[TBL] [Abstract][Full Text] [Related]
27. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma.
Escribà-Garcia L; Alvarez-Fernández C; Tellez-Gabriel M; Sierra J; Briones J
J Transl Med; 2017 May; 15(1):115. PubMed ID: 28549432
[TBL] [Abstract][Full Text] [Related]
28. NK cell tolerance in mixed allogeneic chimeras.
Zhao Y; Ohdan H; Manilay JO; Sykes M
J Immunol; 2003 Jun; 170(11):5398-405. PubMed ID: 12759414
[TBL] [Abstract][Full Text] [Related]
29. The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice.
Vallera DA; Taylor PA; Sprent J; Blazar BR
Transplantation; 1994 Jan; 57(2):249-56. PubMed ID: 7906058
[TBL] [Abstract][Full Text] [Related]
30. Influence of the additional injection of host-type bone marrow on the immune tolerance of minor antigen-mismatched chimeras: possible involvement of double-negative (natural killer) T cells.
Sefrioui H; Billiau AD; Overbergh L; Rutgeerts O; Waer M
Transplantation; 1999 Nov; 68(10):1560-7. PubMed ID: 10589955
[TBL] [Abstract][Full Text] [Related]
31. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
32. Preventing NK cell activation by donor dendritic cells enhances allospecific CD4 T cell priming and promotes Th type 2 responses to transplantation antigens.
Coudert JD; Coureau C; Guéry JC
J Immunol; 2002 Sep; 169(6):2979-87. PubMed ID: 12218112
[TBL] [Abstract][Full Text] [Related]
33. EBV-induced human CD8(+) NKT cells synergise CD4(+) NKT cells suppressing EBV-associated tumours upon induction of Th1-bias.
Xiao W; Li L; Zhou R; Xiao R; Wang Y; Ji X; Wu M; Wang L; Huang W; Zheng X; Tan X; Chen L; Xiong T; Xiong J; Jin Y; Tan J; He Y
Cell Mol Immunol; 2009 Oct; 6(5):367-79. PubMed ID: 19887050
[TBL] [Abstract][Full Text] [Related]
34. A radio-resistant perforin-expressing lymphoid population controls allogeneic T cell engraftment, activation, and onset of graft-versus-host disease in mice.
Davis JE; Harvey M; Gherardin NA; Koldej R; Huntington N; Neeson P; Trapani JA; Ritchie DS
Biol Blood Marrow Transplant; 2015 Feb; 21(2):242-9. PubMed ID: 25459639
[TBL] [Abstract][Full Text] [Related]
35. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.
Fujii S; Shimizu K; Smith C; Bonifaz L; Steinman RM
J Exp Med; 2003 Jul; 198(2):267-79. PubMed ID: 12874260
[TBL] [Abstract][Full Text] [Related]
36. West Nile virus-infected human dendritic cells fail to fully activate invariant natural killer T cells.
Kovats S; Turner S; Simmons A; Powe T; Chakravarty E; Alberola-Ila J
Clin Exp Immunol; 2016 Nov; 186(2):214-226. PubMed ID: 27513522
[TBL] [Abstract][Full Text] [Related]
37. Global unresponsiveness as a mechanism of natural killer cell tolerance in mixed xenogeneic chimeras.
Kawahara T; Rodriguez-Barbosa JI; Zhao Y; Zhao G; Sykes M
Am J Transplant; 2007 Sep; 7(9):2090-7. PubMed ID: 17640313
[TBL] [Abstract][Full Text] [Related]
38. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
[TBL] [Abstract][Full Text] [Related]
39. Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice.
Shimizu K; Goto A; Fukui M; Taniguchi M; Fujii S
J Immunol; 2007 Mar; 178(5):2853-61. PubMed ID: 17312129
[TBL] [Abstract][Full Text] [Related]
40. Cross-presentation of dead-cell-associated antigens by DNGR-1
Balam S; Kesselring R; Eggenhofer E; Blaimer S; Evert K; Evert M; Schlitt HJ; Geissler EK; van Blijswijk J; Lee S; Reis e Sousa C; Brunner SM; Fichtner-Feigl S
Eur J Immunol; 2020 Dec; 50(12):2041-2054. PubMed ID: 32640051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
